In previous studies around FLT3-ITD+ AML combinatorial treatments, FLT3 inhibitors were combined with bromodomain and extra-terminal domain (BET) protein inhibitors and DNA methyltransferase (DNMT) inhibitors [42,43]. This evidence concerns the gene DNMT1 and acute myeloid leukemia.